FINWIRES · TerminalLIVE
FINWIRES

Crompton Greaves Consumer Electricals Gets Solar Pump Order Worth INR718 Million

-- Crompton Greaves Consumer Electricals (NSE:CROMPTON, BOM:539876) has received a letter of empanelment and rate contract worth about 717.5 million Indian rupees from Maharashtra State Electricity Distribution Co., according to a Friday filing on Indian bourses.

The order involves designing, manufacturing, supply, installation, testing and commissioning of 3,540 off-grid solar photovoltaic water pumping systems across Maharashtra, the filing said.

The contract includes warranty, maintenance and remote monitoring systems, and is to be executed within 60 days from the notice to proceed, the filing said.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062